10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Monday, November 21, 2011

Bliss GVS Pharma Ltd:-Buy/sell/growth prospects and recommendation,news and results,target price and analysis,view and outlook,multibagger

Scripscan:Bliss GVS Pharma Ltd

Story:This is an interesting company. They are into pharma and FMCG, making anti-malaria, respiratory, anti-inflammatory and even dermatology products and some personal care products.First let me take the financial performance of the company for H1FY12, they posted a PAT of about Rs 32 crore on a top line of about Rs 132 crore. This results into a PAT margin of 27% which is very rare. In fact, these kind of PAT margin is not enjoyed by the larger pharma and FMCG companies too.Also, they have posted a 23% growth on the top line on a comparable period of FY11 and posted a growth of 24% in the bottom line. That has resulted into an EPS of about Rs 3.50 for the first six months of the year on a low equity of about Rs 10.50 crore.The share has a face value of Re 1. The book value of the share will be at about Rs 24 by 31 March 2012. That means it is available practically exactly at a book value of Re 1.If you see the manufacturing pipeline of the company, they have a very strong brand portfolio, reputed products enjoyed by the name of the company, and the plant is located at Palghar in Maharashtra.The shareholding pattern is also quite interesting - 65% held by the promoter, 13% by HNIs and about 20-22% is with the public. So the share is available at a PE multiple of three times. It’s a totally debt free company. Additionally, the kind of profitability on an annualized basis is of about Rs 70 crore which makes it a very interesting bet.If somebody can keep it in the portfolio for about two years, I think it is capable of giving a return of about 150-200%. Even on a shorter horizon, maybe in six months or so, the share is capable to give 30% returns.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner